Additionally, Vertex’s next-generation treatment VX-993 failed in its Phase 2 acute pain study. Stifel indicated these results suggest Vertex "may have nearly maximized the efficacy from the NaV1.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback